Table 2.
Phenotypic Characteristics of the IBD Patients.
| Diagnosis | UC | CD | ||
|---|---|---|---|---|
| Cohort | NIDDK | Brisbane | NIDDK | Brisbane |
| Age at diagnosis, mean ± s.d. (range) | 32.7 ± 16 (3–82) | 32.8 ± 14.6 (3–75) | 26.9 ± 13.1 (0–80) | 27.1 ± 11.1 (2–66) |
| Age at diagnosis of CD (Montreal A) | ||||
| A1 (≤16 years) | 20 (14.4) | 26 (10.2) | 48 (19) | 23 (10.3)*2 |
| A2 (17 – 40 years) | 83 (59.7) | 155 (60.4) | 170 (67.2) | 173 (77.2) |
| A3 (> 40 years) | 36 (25.9) | 73 (28.5) | 35 (13.8) | 28 (12.5) |
| Disease duration > 3 years (%) | 110 (79.1) | 226(88.3)* | 225 (88.9) | 204 (91.1) |
| Disease location, CD (Montreal L) | ||||
| L1 ileal | 56 (22.1) | 109 (48.7)** | ||
| L2 colonic | 64 (25.3) | 26 (11.6) | ||
| L3 ileocolonic | 128 (50.6) | 88 (39.3) | ||
| Perianal ± other involvement | 78 (30.8) | 63 (28.1) | ||
| Disease behavior, CD (Montreal B) | ||||
| B1 non-stricturing, non enetrating | 113 (44.7) | 83 (37.1) | ||
| B2 stricturing | 63 (24.9) | 64 (28.6) | ||
| B3 penetrating – excludes perianal | 71 (28.1) | 77 (34.4) | ||
| Surgery for IBD – Yes (%) | 22 (15.8) | 66(25.8)** | 136 (53.8) | 147 (65.6)* |
| Disease location, UC (Montreal E) | ||||
| E1 ulcerative proctitis | 21 (15.1) | 12 (4.7)** | ||
| E2 left-sided UC (distal UC) | 37 (26.6) | 91 (35.5) | ||
| E3 extensive UC (pancolitis) | 79 (56.8) | 136 (53.1) | ||
| Exposure to IBD Medication – Yes (%) | ||||
| 5-Amino Salicylic Acids3 | 127 (91.4) | 212 (82.8) | 189 (74.7) | 62 (27.7) |
| Immunomodulators4 | 64 (46.0) | 108 (42.2) | 167 (66.0) | 167 (74.6) |
| Biologics5 | 23 (16.5) | 23 (9.0) | 100 (39.5) | 74 (33.0)* |
2
P-value <0.05 denotes significantly different proportions of affection subsets between NIDDK and Brisbane; specific values are cited in results section
3
5-ASAs:Balsalazide, Mesalamine, Olsalazine, Sulfasalazine
4
Immunomodulators: Imuran, Methotrexate, Purinethol, Neoral
5
Biologics: Adalimumab, Certolizumab, Infliximab